Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors

International Journal of Hematology
Yukinori NakamuraYukio Tanizawa

Abstract

Acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with significant morbidity and mortality. In the present study, we retrospectively evaluated whether soluble interleukin-2 receptor (sIL-2R) index, defined as the ratio of serum sIL-2R levels at neutrophil engraftment to those at the pre-conditioning regimen, was predictive of acute GVHD among 51 patients who underwent allogeneic HSCT as their first transplantation and achieved engraftment. The median sIL-2R index was 3.6, and the sIL-2R values were positively associated with acute GVHD severity (grade 0-I: 3.8 ± 2.0 vs. grade II-IV: 7.1 ± 5.7; P = 0.05). Grade II-IV acute GVHD had a cumulative incidence of 31.4 %, and was significantly more frequent among patients with an sIL-2R index of ≥4.5 (≥4.5: 50.0 % vs. <4.5: 21.2 %; P = 0.03). Multivariate analysis revealed that an sIL-2R index of ≥4.5 [hazard ratio (HR) 3.5, P < 0.01] and donor age of >35 years (HR 3.8, P = 0.02) were significant risk factors for grade II-IV acute GVHD. Therefore, increased sIL-2R levels from baseline to engraftment might predict the risk of moderate-to-severe acute GVHD after allogeneic HSCT from an unrelated donor.

References

Oct 15, 1990·Annals of Internal Medicine·L A Rubin, D L Nelson
Apr 2, 1998·The New England Journal of Medicine·J A HansenC Anasetti
Oct 4, 2008·Blood·Sophie PaczesnyJames L M Ferrara
Nov 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Theresa HahnOlle Ringdén
May 19, 2010·Bone Marrow Transplantation·D D PoutsiakaD R Snydman
Jul 14, 2010·Bone Marrow Transplantation·K J AugustJ T Horan
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John E LevineStefanie Sarantopoulos
Aug 7, 2012·Bone Marrow Transplantation·Y-B Chen, C S Cutler
Jul 23, 2013·Bone Marrow Transplantation·O BlennowM Remberger
Aug 21, 2013·International Journal of Hematology·Sophie PaczesnyChristy Mumaw
Jun 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lawrence ChangSung Won Choi
Jul 16, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robert P NelsonSophie Paczesny
Nov 18, 2014·British Journal of Haematology·Enric Carreras

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.